Conclusions
DDIs may occur between DAA drugs and TKIs and may lead to severe toxic effects. Indeed, DAA drugs can inhibit CYP3A4 agents (glecaprevir, grazoprevir) and/or P-gp agents (voxilaprevir, ledipasvir) and interact with anticancer TKIs that are mostly CYP3A4 and/or P-gp substrates (gefitinib, afatinib, erlotinib, crizotinib, ceritinib, lorlatinib, brigatinib, capmatinib etc.) (14,15). Clinicians should be aware of the major consequences of DDIs and the importance of plasma drug monitoring in cancer patients receiving treatment for HCV.